WHO Updates Opioid Treatment Guidelines
Analysis based on 6 articles · First reported Apr 02, 2026 · Last updated Apr 07, 2026
The updated guidelines from World Health Organization could positively impact pharmaceutical companies producing Methadone and Buprenorphine, especially those with long-acting injectable formulations, by potentially increasing demand for these treatments. The broader healthcare market may see increased investment in opioid dependence treatment infrastructure.
The World Health Organization (WHO) has announced significant updates to its forthcoming guidelines for the treatment of opioid dependence and the community management of opioid overdose. These updates reaffirm strong recommendations for opioid agonist maintenance treatment (OAMT) using Methadone and oral Buprenorphine. Crucially, the World Health Organization has extended its guidance to include new formulations of long-acting injectable Buprenorphine as a conditional recommendation, aiming to expand treatment options and accessibility. The World Health Organization highlighted that opioid dependence remains a major global health burden, with an estimated 61 million people engaging in non-medical opioid use in 2023 and approximately 450,000 drug-related deaths linked to opioids. Despite 64 million people living with drug use disorders, fewer than 10% currently receive treatment. The full guidelines, which underwent a rigorous development process considering benefits, risks, cost-effectiveness, and equity, are expected to be published later in 2026 or early 2027.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard